Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.

ABSTRACT: The identification of echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) fusion gene in non-small cell lung cancer (NSCLC) has radically changed the treatment of a subset of patients harboring this oncogenic driver. Crizotinib was the first ALK tyrosine kinase inhibitor to receive fast approval and is currently indicated as the first-line therapy for advanced, ALK-positive NSCLC patients. However, despite crizotinib's efficacy, patients almost invariably progress, with the central nervous system being one of the most common sites of relapse. Different mechanisms of acquired resistance have been identified, including secondary ALK mutations, ALK copy number alterations and activation of bypass tracks. Different hig

SUBMITTER: Santarpia M 

PROVIDER: S-EPMC5503498 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature